PHARMExcel is thrilled to be recognised at the 2024 OBN Awards for its outstanding contributions to clinical research, particularly within the ophthalmology and rare disease space. The company’s dedication to driving meaningful advancements for patients has led to long-standing collaborations with innovative global biotechs and leading research institutions, such as Moorfields Eye Hospital and Rare Disease Research Partners, positioning PHARMExcel as a valuable clinical trials partner in these transformative fields.
At the OBN Awards, PHARMExcel’s work was acknowledged for its significant impact on accelerating clinical trials and providing tailored solutions that meet the unique needs of ophthalmology biotechs and rare disease healthcare companies.
Yvanne Enever, CEO and Founder of PHARMExcel, commented:
“We are proud to be part of the journey that is shaping the future of rare disease treatments and ophthalmic innovations. Our partnerships with Moorfields Eye Hospital and Rare Disease Research Partners allow us to offer unmatched expertise and resources to accelerate clinical research programs. This recognition is a reflection of our team’s commitment to making a real difference for patients in need of new, life-changing therapies.”
Margaret Irwin, Head of Clinical Operations, added:
“Working alongside biotechs and researchers in the ophthalmology and rare disease sectors is a privilege. These are complex fields, where the need for precision, speed, and expertise is critical. Our collaborative approach and strong CRO-Sponsor relationships ensure that we provide the highest level of support to bring groundbreaking treatments to market.”
This recognition underscores PHARMExcel’s role in providing flexible, high-quality services tailored to the evolving needs of global pharma, biotech and medtech across multiple therapeutic areas. Celebrating its 15th year, PHARMExcel remains committed to accelerating clinical trial outcomes, especially in areas where traditional CROs may not offer the flexibility and ‘pick and mix’ service model required.
"Congratulations on reaching this milestone! The PHARMExcel team consistently exceeds expectations, offering a depth of expertise and attention to detail that sets them apart. Their ability to adapt to the needs of our projects while maintaining the highest standards makes them an invaluable partner in clinical research."
Professor Rajiv Jalan, Professor of Hepatology and Head of the Liver Failure Group at University College London.
"Congratulations to the whole PHARMExcel team on this fantastic milestone Your expertise was instrumental in navigating the complexities of our ATMP clinical trial. Your hands-on approach, attention to detail, and deep understanding of regulatory frameworks gave us the confidence to move forward, knowing our project was in the best possible hands."
Mark Lowdell, CSO at InMuneBio Inc
"PHARMExcel’s passion for our project, the professionalism and expertise demonstrated, combined with direct access to the CEO sets PHARMExcel apart from other CROs."
Laurence Marsteller, CEO, Radiance Therapeutics
For more information on PHARMExcel’s work in ophthalmology and rare diseases, or to explore how we can support your clinical research needs, visit our dedicated web page here.
PHARMExcel and Moorfields Eye Hospital: A Visionary Partnership in Ophthalmology Clinical Research
What are the 4 key values that underpin a successful CRO-Sponsor relationship?
Your Research, Our Priority: PHARMExcel’s Commitment to Delivering Quality Every Time
Forging Paths: A Closer Look at Rare Disease Clinical Trials in the UK
